Gapping up
In reaction to earnings/guidance:
META +17.7% (also Initiates dividend; increases share repurchase program by $50 bln), COUR +9.5%, DECK +9.3% (also CEO to retire, names new CEO), CLX +8.1%, AMZN +6.9%, NOV +5.7%, REGN +4.2%, MTX +3.6%, HOLX +3.5%, BMY +3.4%, PFSI +3.3%, POST +3.2%, WT +3.2%, OTEX +3.1%, CI +3.1%, CPT +2.1%, HIG +2%, DXC +1.6% (also names new CEO), CVX +1.4%, XOM +0.9%
Other news:
BBIO +6.2% (results from the Japan Phase III trial of acoramidis)
PLUG +6% (signed a contract to deliver a Basic Engineering and Design Package (BEDP) for a 500 megawatt (MW) electrolyzer project in Europe) CDXS +5.1% (creates transposase enzyme with seqWell)
CABA +4.5% (FDA grants Orphan Drug Designation to CABA-201)
REGN +4.2% (linvoseltamab receives EMA Filing acceptance for treatment of relapsed/refractory multiple myeloma)
TYRA +3% (receives FDA rare pediatric disease designation for TYRA-300)
ETON +3% (commercial availability of ultra-rare disease product Nitisinone Capsules)
PLTR +2.6% (partnership with Coles Supermarkets Australia)
PII +2.5% (increases dividend)
ZUO +2.5% (to reduce workforce; reaffirms Q4 guidance)
CIFR +2.4% (operational update)
RKLB +2% (prices offering of $300 mln of 4.250% convertible senior notes due 2029)
HCM +1.7% (announces that Inmagene exercises option to license two drug candidates as part of strategic partnership )
HUT +1.7% (confirms it negotiated an agreement with the new owners of two of Hut 8's managed services sites)
AEO +1.6% (authorizes new 30 mln share repurchase program)
NRIX +1.3% (announces publication identifying new class of BTK mutations susceptible to NX-2127)
ELF +1.2% (launched one of the first beauty shopping apps for Apple (AAPL) Vision Pro )
MRCY +1% (signs subcontract with RTX related to US Army project)
Analyst comments:
ALGM +2.4% (upgraded to Outperform from Peer Perform at Wolfe Research)
M +1.1% (upgraded to Neutral from Sell at Citigroup)
CMS +0.7% (upgraded to Buy from Neutral at Guggenheim)
SAP +0.5% (upgraded to Buy from Hold at Jefferies)